SOAT1 and COVID-19: Different synthetic immunomodulatory agents such as corticosteroids, interleukin receptor antagonists, JAK/STAT inhibitors and monoclonal antibodies like tocilizumab, sarilumab, infliximab and adalimumab that target specific cytokines are being evaluated for treatment of COVID-19 patients.